Psychiatry

A recent study found Black individuals had a sharp increase in midlife deaths from suicide, drug overdose, and alcoholic liver disease after 2015.

Vision issues were linked to an increased risk of suicidal ideation, suicidal behavior, and suicide death, particularly among adolescents.

In an interview with HCPLive, Rishi Kakar, MD, discussed the positive long-term xanomeline-trospium data from EMERGENT-4.

A new study found individuals with PTSD face rapid transitions between neutral and negative emotional states.

In an interview with HCPLive, Sunny Rai, PhD, shed light on a new study regarding how an AI model failed to detect depression in Black individuals.

A new study found extending postpartum Medicaid from 60 days to 12 months is linked to new mothers being more likely to seek mental health care for perinatal mood and anxiety disorders.

A new study found a single low dose of esketamine given shortly after childbirth reduced major depressive episodes at 42 days postpartum by about 3 quarters.

Patients on psilocybin for depression or anxiety reported tolerable adverse events, including headache, nausea, anxiety, dizziness, and elevated blood pressure.

Sibling control analyses showed acetaminophen use during pregnancy was not associated with an offspring’s risk of autism, ADHD, or intellectual disability.

A study using machine learning models found “I” usage on Facebook posts does not predict depression severity in Black individuals.

EMERGENT-3 trial showed xanomeline-trospium was effective in improving schizophrenia symptoms at 52 weeks, for participants who took either placebo or KarXT in acute trials.

A new study showed how taking alcohol use disorder medication following an alcohol-related hospitalization discharge was linked to a reduction in return to hospital in 30 days.

Lykos Therapeutics announced the FDA accepted its NDA for MDMA-assisted therapy for individuals with PTSD on February 9, 2024, backed by phase 3 data showing the drug’s efficacy.

Although still recruiting, the first patient was randomized to receive NBI-1070770 for major depressive disorder in a phase 2 trial assessing efficacy, safety, and tolerability.

The study found the odds of a perinatal PTSD diagnosis were greater for people aged 15 – 26 years, more comorbidities, and a lower income of poverty.

The FDA approved iloperidone for acute treatment of bipolar I disorder on April 02, 2024, according to Vanda Pharmaceuticals.

Autism presents differently in males and females, which could explain why fewer females are diagnosed. Females are also often limited or excluded in autism research.

This March 2024 psychiatry month in review highlights positive phase 2b and phase 2a data for drugs targeting treatment-resistant depression, generalized anxiety disorder, and PTSD.

Abusing psychoactive substances, such as ADHD medication, cannabis, and nicotine, not only creates an addiction but can impact mental distress.

A phase 2a open-label study found BL-003 for treatment-resistant depression was well-tolerated and any acute effects resolved on average in less than 2 hours.

A new study found sleep and emotional well-being are impacted days before women get their period.

In a new study, investigators evaluated if social contact influenced the age gap between biological age, estimated with artificial intelligence (AI), and chronological age.

In a recent UK study, more than half of stroke survivors developed depression within 18 years.

The hospitalization risk was reduced to up to 75% for patients with heart disease treated with both antidepressants and psychotherapy to manage anxiety or depression symptoms.

Bionomics announced the release of the full dataset analysis of the ATTUNE phase 2b trial; the data suggests BNC210 for PTSD could have an advantage over approved medications.